HZNP News and Press, Horizon Therapeutics Public Limited Company From 08/31/22

Summary Shares of Horizon Therapeutics are down 50% from last year's highs, a consequence of a prolonged biotech market and recent setbacks. The Tepezza growth scare is the main reason the stock is trading at current levels, but Tepezza remains well-positioned for long-term growth...

Summary John Paulson’s 13F portfolio value decreased from $3.25B to $2.03B this quarter. Paulson & Company dropped SPDR Gold ETF and Exxon Mobil while increasing Horizon Therapeutics. The top three positions are at 43% of the portfolio. This article is part of...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in September: Morgan Stanley 20 th Annual Global Healthcare Conference Date: Tuesday, Sept. 13, 2022 Presentation Time: 2:05 p.m. ET Locati...

Shares have lost 40% of their value year to date. Tepezza sales should reaccelerate into the back half of 2022 and 2023 as the drug makes inroads into chronic TED market. Krystexxa continues to experience respectable growth in the uncontrolled gout market and Horizon has multiple ...

Horizon Therapeutics ( NASDAQ: HZNP ) and Q32 Bio signed a collaboration and option agreement to develop ADX-914 for treating autoimmune diseases. Q32 expects to begin a phase 2 trial in atopic dermatitis (eczema) later this year and is planning to start a phase 2 stud...

Viridian Therapeutics ( NASDAQ: VRDN ) said VRDN-001 was safe and showed clinical activity in an ongoing phase 1/2 trial in patients with with active thyroid eye disease (TED). TED is a rare autoimmune disease in which the immune system attacks the tissues around th...

Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of auto...

UBS has downgraded Horizon Therapeutics ( NASDAQ: HZNP ) to Neutral from Buy, citing a challenging setup for the biotech’s thyroid eye disease therapy Tepezza. In 2020, the FDA approved the drug for the autoimmune condition characterized by eye bulging, double vision,...

Gainers: Kaspien Holdings ( KSPN ) +136% . Heart Test Laboratories ( HSCS ) +92% . Poseida Therapeutics ( PSTX ) +74% . Eargo ( EAR ) +73% . Ping Identity ( PING ) +60% . Applied DNA ( APDN ) +53% . Golden Sun ( ...

Horizon Therapeutics Public Limited Company (HZNP) Q2 2022 Results Earnings Conference Call August 3, 2022, 08:00 AM ET Company Participants Tina Ventura - Senior Vice President, Chief Investor Relations Officer Tim Walbert - Chairman, President and Chief Executive O...